FATE at a glance
FATE THERAPEUTICS INC (FATE, SEC CIK 1434316) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), FATE THERAPEUTICS INC (FATE) reported revenue of $6.6 million (down 51.2% from FY2024) and a net loss of $136.3 million. Diluted EPS was -$1.15.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding FATE THERAPEUTICS INC (FATE) shares worth $102.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Valamehr Bahram on August 4, 2026 of 43,947 shares at $2.46 per share.
- In the last 90 days, FATE insiders reported 0 open-market purchases ($0) and 2 open-market sales ($204K) on Form 4, a net sale of $204K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.6M
- −51.2% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$204K
- 13F holders
- 22 funds
- $102.5M · −1 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Collaboration revenue $2.1M, up from $1.9M YoY
- Research and development expense $24.4M, down from $27.4M YoY
- General and administrative expense $8.8M, down from $11.4M YoY
- Clinical trial expense increased $1.7M, offsetting lower compensation and consulting costs
- Cash outlook supported by $7.9M FT819 and $4.0M FT836 CIRM awards; funding sufficient for at least twelve months
Risk Factors
- FDA’s May 2026 selection of FT819 for the CDRP Program created reliance on enhanced CMC engagement without assurance of faster development
- Manufacturing risk heightened by unvalidated commercial-scale processes and potential FDA-required process changes
- Regulatory approval risk remains acute because no product candidate has completed clinical development or received approval
- Clinical execution risk from patient recruitment, competing trials, and potential clinical holds
- Supply concentration risk from dependence on internal San Diego facilities and third parties for manufacturing components
AI summary of the FATE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- $15.0M CIRM CLIN2 grant supports RECLAIM-LN, reducing Fate’s funding burden for FT819’s lupus nephritis development
- RECLAIM-LN is a Phase 2 potentially registrational trial targeting approximately 53 refractory patients
Item 8.01: Other Events
- CIRM awarded Fate Therapeutics a $15 million grant on September 25, 2026
- Funding supports Phase 2 RECLAIM-LN clinical trial of FT819
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Exhibit 99.1 contains Fate Therapeutics’ detailed financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 revenue $2.1M; net loss $30.2M, or $(0.25) per share, versus $(0.29) in Q2 2025
- Cash, equivalents, and investments $153.8M after a $21M quarterly decrease; operating runway expected into 2028
Item 5.07: Submission of Matters to a Vote of Security Holders
- All four proposals approved at June 12, 2026 annual meeting; three Class I directors elected through 2029
- Shareholder support strongest for Ernst & Young ratification, with 86,552,927 votes for and 308,582 against
AI summaries of FATE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for FATE
Don't miss the next FATE filing
- Alerts as it files. A push when FATE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut FATE, by share count.
- Ask anything. An AI agent that reads every FATE filing and answers with sources.
FATE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Valamehr Bahram | Sell | Aug 4, 2026 | 43,947 | $2.46 |
| TAHL CINDY | Sell | Aug 4, 2026 | 38,800 | $2.46 |
| Xu Yuan | A | Jun 12, 2026 | 87,900 | - |
| Redmile Group, LLC | A | Jun 12, 2026 | 87,900 | - |
| Lee Michael Stewart | A | Jun 12, 2026 | 87,900 | - |
| RASTETTER WILLIAM H | A | Jun 12, 2026 | 87,900 | - |
| EPSTEIN ROBERT S | A | Jun 12, 2026 | 87,900 | - |
| Jooss Karin | A | Jun 12, 2026 | 87,900 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $13.6M | $6.6M |
| Operating Income | - | -$210.3M | -$147.7M |
| Net Income | -$160.9M | -$186.3M | -$136.3M |
| Op. Margin | - | -1542.6% | -2222.4% |
| Net Margin | - | -1366.5% | -2051.1% |
| Balance Sheet | |||
| Total Assets | $506.2M | $440.7M | $318.9M |
| Equity | - | $318.7M | $207.2M |
| ROE | - | -58.4% | -65.8% |
| Per Share | |||
| EPS | $-1.64 | $-1.64 | $-1.15 |
| Cash Flow | |||
| Operating CF | - | -$122.9M | -$106.1M |
| CapEx | $6.2M | $730K | $6.0M |
Source: XBRL data in FATE THERAPEUTICS INC (FATE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate FATE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $102.5M |
| Q1 2026 | 23 | $47.3M |
| Q4 2025 | 23 | $36.5M |
| Q3 2025 | 24 | $46.8M |
| Q2 2025 | 26 | $48.3M |
| Q1 2025 | 22 | $27.4M |
| Q4 2024 | 20 | $46.8M |
| Q3 2024 | 18 | $77.4M |
- AQR Capital Management+835.7K (+28%)
- Goldman Sachs Group+721.4K (+54%)
- Vanguard Portfolio Management LLC+411.3K (+10%)
- Vanguard Capital Management LLC+253.5K (+6%)
- Two Sigma Investments+123.1K (+4%)
- BlackRock−2.77M (-28%)
- State Street Corp−1.70M (-75%)
- Northern Trust−569.2K (-70%)
- Dimensional Fund Advisors−531.6K (-60%)
- BNY Mellon−295.6K (-96%)
- Millennium Management+2.43M
- T. Rowe Price Group−76.6K
- Prudential Financial−26.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 178 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
FATE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | Apr 23, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
FATE SEC filings: frequently asked questions
Are FATE insiders buying or selling?
In the last 90 days, FATE THERAPEUTICS INC (FATE) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $203,506 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold FATE stock?
As of June 30, 2026, the largest FATE THERAPEUTICS INC (FATE) holders among the 13F filers tracked by SignalX were BlackRock ($19.7 million), Vanguard Portfolio Management LLC ($12.3 million), Vanguard Capital Management LLC ($12.0 million), AQR Capital Management ($10.4 million), Two Sigma Investments ($9.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was FATE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), FATE THERAPEUTICS INC (FATE) reported revenue of $6.6 million (down 51.2% from FY2024) and a net loss of $136.3 million. Diluted EPS was -$1.15. The figures come from the XBRL data in the 10-K.
What did FATE report in its latest 8-K?
FATE THERAPEUTICS INC (FATE) filed an 8-K on September 28, 2026 reporting Item 8.01 (Other Events). $15.0M CIRM CLIN2 grant supports RECLAIM-LN, reducing Fate’s funding burden for FT819’s lupus nephritis development.
What are the latest FATE SEC filings?
FATE THERAPEUTICS INC (FATE) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on August 5, 2026.
What is FATE's SEC CIK number?
FATE THERAPEUTICS INC (FATE)'s SEC Central Index Key (CIK) is 1434316. EDGAR lists every FATE filing under that number.
Ask anything about FATE
The research agent reads FATE's filings, financials, insider trades and 13F holders, then answers with sources.